Effect of Rosa canina on non alcoholic fatty liver

Investigation of effectiveness of Rosa canina on liver enzymes in patients with nonalcoholic fatty liver

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017011514333N65

Enrollment

Registered

2017-03-09

Start date

2017-02-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver(NAFLD). Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: The intervention group will receive a 500 mg pill containing dog rose fractions (fraction of Rosa canina, gelatin solution5% and avicel) per day for 8 weeks. Intervention 2: The contro

Treatment - Drugs

Placebo

The intervention group will receive a 500 mg pill containing dog rose fractions (fraction of Rosa canina, gelatin solution5% and avicel) per day for 8 weeks.

The control group will receive a 500 mg placebo pill containing lactose powder, gelatin solution5%, and avicel, per day for 8 weeks.

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diagnosis of non-alcoholic fatty diseases based on AST and ALT level more than 30 in men and 20 in women and also liver ultrasound; Aged between 30-65 years; BMI greater than 25; Non-use of antioxidant supplements during one month prior to sampling; Non-acute cardiac disease, renal, infectious, diabetes, hepatitis B or C and other liver diseases; Not being on an intense increasing or decreasing diet weight during the last three months prior to sampling; lack of effective drugs on weight during the last three months prior to sampling; not using medications that may be associated with the disease (methotrexate, amiodarone, tamoxifen, corticosteroids, valproic acid). Exclusion criteria: Not wanting to continue the study; Use of drugs that affect the liver; The risk of diseases that require special treatment; pregnancy during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver enzymes. Timepoint: Baseline, 48 hours after the end of the study (study will take 8 weeks). Method of measurement: Based on the results of blood tests (including ALT and AST).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Hossein Farzaei

Kermanshah University of Medical Sciences

Mh.farzaei@gmail.com+98 83 3426 6780

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026